Real world study of trastuzumab(Zercepac) in the treatment of HER2 positive breast cancer

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100043781

Enrollment

Unknown

Registered

2021-02-28

Start date

2021-04-01

Completion date

Unknown

Last updated

2021-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Zercepac:Zercepac

Eligibility

Sex/Gender

Female

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: HER2 positive breast caner patients.

Exclusion criteria

Exclusion criteria: 1. Patients who refuse to participate this study or to be followed up; 2. Patients who have been in other intervention studies in four weeks.

Design outcomes

Primary

Measure	Time frame
PFS;	—

Countries

China

Contacts

Public ContactFeng Jifeng

Jiangsu Province Cancer Hospital

fjif@medmail.com.cn+86 25-83283318

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026